Cyclerion Therapeutics, Inc (CYCN)

Etorro trading 970x250
Cyclerion Therapeutics, Inc (CYCN) Logo

About Cyclerion Therapeutics, Inc

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer’s disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142

Cyclerion Therapeutics, Inc News and around…

Latest news about Cyclerion Therapeutics, Inc (CYCN) common stock and company :

As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year
11 May, 2022 Yahoo! Finance

The recent 14% drop in Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) stock could come as a blow to insiders who...

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
04 May, 2022 Yahoo! Finance

Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) study enrollment closed; topline data expected in Q2 2022Cognitive Impairment Associated with Schizophrenia (CIAS) study enrollment closed; topline data expected in Q3 2022Alzheimer’s Disease with vascular pat

Stocks That Hit 52-Week Lows On Wednesday
20 Apr, 2022 FinancialContent

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Apr, 2022 FinancialContent

Gainers Enveric Biosciences (NASDAQ:ENVB) shares moved upwards by 11.0% to $0.36 during Tuesday's after-market session. Enveric ...

Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans?
27 Feb, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
24 Feb, 2022 Yahoo! Finance

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022 Phase 2a study in Alzheimer’s Disease with vascular pathology (ADv) enrollment ongoing CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
23 Feb, 2022 Yahoo! Finance

Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairmentCAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and ac

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board
01 Feb, 2022 Yahoo! Finance

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creationCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
26 Jan, 2022 Yahoo! Finance

Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognitionCAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv). “The need for effective new treatments for Alzheimer’s disease is immense, and

12 Health Care Stocks Moving In Monday's Pre-Market Session
10 Jan, 2022 FinancialContent

Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The ...

Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
15 Dec, 2021 Yahoo! Finance

The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

68 Biggest Movers From Wednesday
26 Nov, 2021 FinancialContent

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced ...

12 Health Care Stocks Moving In Thursday's After-Market Session
25 Nov, 2021 FinancialContent

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of ...

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year
25 Nov, 2021 Yahoo! Finance

Viewing insider transactions for Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) over the last year, we see that...

12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 40.19% to $14.3 during Wednesday's after-market session. At the close, ...

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
11 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021. A pre-recorded corporate presentation will be available on-demand beginning on Thursday, Nov. 18 and will remain available for 30 days in the investor section of the Cyclerion w

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
09 Nov, 2021 Yahoo! Finance

First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS); Topline clinical results expected in H1 2022 CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to d

Exclusive: Startup raises $27M to find brain-based biomarkers
08 Nov, 2021 Yahoo! Finance

Infused with $27 million from General Catalyst and Casdin Capital, Beacon Biosignals is planning to capitalize on the resurgence in neuroscience across the biotech field.

Analysts Expect 24% Gains Ahead For IEIH
03 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside
20 Oct, 2021 FinancialContent

Truistanalyst Joon Lee hasinitiated coverageofCyclerion Therapeutics Inc(NASDAQ: CYCN) with a Buy ...

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
20 Oct, 2021 FinancialContent

Upgrades For Iridium Communications Inc (NASDAQ:IRDM), BWS Financial upgraded the previous rating of Neutral to Buy. Iridium ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Oct, 2021 FinancialContent

Gainers F-star Therapeutics (NASDAQ:FSTX) shares increased by 18.74% to $7.6 during Wednesday's pre-market session. ...

David Greenspan’s Slate Path Capital is Buying Coinbase, Stitch Fix, and More
11 Oct, 2021 Yahoo! Finance

In this article, we discuss the top stocks recently acquired by David Greenspan’s Slate Path Capital according to analysts. If you want to skip our detailed analysis of Greenspan’s history, investment philosophy, and hedge fund performance, go directly to David Greenspan’s Slate Path Capital is Buying These 5 Stocks. David Greenspan instilled his efforts at […]

Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions?
10 Oct, 2021 Yahoo! Finance

Every investor in Cyclerion Therapeutics, Inc. ( NASDAQ:CYCN ) should be aware of the most powerful shareholder groups...

Analysts Forecast 21% Upside For IEIH
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
24 Sep, 2021 FinancialContent

Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:TENB) from Hold to Buy. In the second quarter, Tenable ...

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
22 Sep, 2021 Yahoo! Finance

Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairmentCAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small molecule soluble guanylate cyclase (sGC) stimulator reduced markers associated with neuroinflammation in multiple precli

Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
08 Sep, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th.Cantor Fitzgerald Virtual Global Healthcare C

Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry?
26 Aug, 2021 Yahoo! Finance

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
23 Aug, 2021 Yahoo! Finance

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer’s disease therapiesCAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 25-26, 2021. Chris Winrow, Ph.D., Head o

Cyclerion Therapeutics, Inc (CYCN) is a NASDAQ Common Stock listed in , ,

970x250